Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growthGlobeNewsWire • 02/24/25
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology PortfolioGlobeNewsWire • 02/24/25
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer TestGlobeNewsWire • 02/06/25
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) AssayGlobeNewsWire • 02/05/25
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink IntegrationGlobeNewsWire • 02/05/25
Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine ConferenceGlobeNewsWire • 01/29/25
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & GynecologyGlobeNewsWire • 01/21/25
Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk InsightsBusiness Wire • 01/15/25
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer HistoryGlobeNewsWire • 01/09/25
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/25
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility ReportGlobeNewsWire • 01/06/25
MYGN Stock Might Gain From the New Recognition of RiskScore StudyZacks Investment Research • 12/20/24
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human GeneticsGlobeNewsWire • 12/19/24
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?Zacks Investment Research • 12/17/24
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic TestingGlobeNewsWire • 12/10/24